Abstract
IntroductionThere is no curative treatment available for patients with chemotherapy relapsed or refractory CD19+ B cells-derived acute lymphoblastic leukaemia (r/r B-ALL). Although CD19-targeting second-generation (2nd-G) chimeric antigen receptor (CAR)-modified T...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have